|
|
Prepublished online as a Blood First Edition Paper on June 21, 2002; DOI 10.1182/blood-2002-04-1199.
 Previous Article | Table of Contents | Next Article 
Blood, 1 October 2002, Vol. 100, No. 7, pp. 2292-2302
REVIEW ARTICLE
The World Health Organization (WHO) classification of the
myeloid neoplasms
James W. Vardiman,
Nancy
Lee Harris, and
Richard D. Brunning
From the Department of Pathology, University of
Chicago, IL; Department of Pathology, Massachusetts General Hospital
and Harvard Medical School, Boston; and Department of Laboratory
Medicine and Pathology, University of Minnesota, Minneapolis.
A World Health Organization (WHO) classification of hematopoietic
and lymphoid neoplasms has recently been published. This classification
was developed through the collaborative efforts of the Society for
Hematopathology, the European Association of Hematopathologists, and
more than 100 clinical hematologists and scientists who are
internationally recognized for their expertise in hematopoietic
neoplasms. For the lymphoid neoplasms, this classification provides a
refinement of the entities described in the Revised European-American
Lymphoma (REAL) Classification a system that is now used worldwide. To
date, however, there has been no published explanation or rationale
given for the WHO classification of the myeloid neoplasms. The purpose
of this communication is to outline briefly the WHO
classification of malignant myeloid diseases, to draw attention
to major differences between it and antecedent classification schemes,
and to provide the rationale for those differences.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Letter in Blood Online:
-
Diagnostic criteria for acute erythroleukemia
- Dale M. Selby, Riccardo Valdez, Bertram Schnitzer, Charles W. Ross, and William G. Finn
Blood 2003 101: 2895.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
M. A. Sekeres, P. Elson, M. E. Kalaycio, A. S. Advani, E. A. Copelan, S. Faderl, H. M. Kantarjian, and E. Estey
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients
Blood,
January 1, 2009;
113(1):
28 - 36.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Sekeres, J. P. Maciejewski, A. A.N. Giagounidis, K. Wride, R. Knight, A. Raza, and A. F. List
Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic Syndromes
J. Clin. Oncol.,
December 20, 2008;
26(36):
5943 - 5949.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Theocharides, J. R. Passweg, M. Medinger, R. Looser, S. Li, H. Hao-Shen, A. S. Buser, A. Gratwohl, A. Tichelli, and R. C. Skoda
The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders
Haematologica,
December 1, 2008;
93(12):
1890 - 1893.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. K. Ahn, H.-S. Cha, E.-M. Koh, S.-H. Kim, Y. G. Kim, C.-K. Lee, and B. Yoo
Behcet's disease associated with bone marrow failure in Korean patients: clinical characteristics and the association of intestinal ulceration and trisomy 8
Rheumatology,
August 1, 2008;
47(8):
1228 - 1230.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Spivak and R. T. Silver
The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal
Blood,
July 15, 2008;
112(2):
231 - 239.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Cazzola
Myelodysplastic syndrome with isolated 5q deletion (5q- syndrome). A clonal stem cell disorder characterized by defective ribosome biogenesis
Haematologica,
July 1, 2008;
93(7):
967 - 972.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Rollison, N. Howlader, M. T. Smith, S. S. Strom, W. D. Merritt, L. A. Ries, B. K. Edwards, and A. F. List
Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs
Blood,
July 1, 2008;
112(1):
45 - 52.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Xiao, Y. Zhang, L. Li, L. Nie, L. Yang, and S. Xu
The Janus kinase 2 (JAK2) V617F mutation in Chinese patients with chronic myeloproliferative disorders
Haematologica,
May 1, 2008;
93(5):
787 - 788.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Liu, R. Kralovics, Z. Rudzki, B. Grabowska, A. S. Buser, D. Olcaydu, H. Gisslinger, R. Tiedt, P. Frank, K. Okon, et al.
A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia in a Polish family
Haematologica,
May 1, 2008;
93(5):
706 - 714.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Passamonti, E. Rumi, M. Caramella, C. Elena, L. Arcaini, E. Boveri, C. Del Curto, D. Pietra, L. Vanelli, P. Bernasconi, et al.
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis
Blood,
April 1, 2008;
111(7):
3383 - 3387.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Li, R. Kralovics, G. De Libero, A. Theocharides, H. Gisslinger, and R. C. Skoda
Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations
Blood,
April 1, 2008;
111(7):
3863 - 3866.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. C. Attar, D. J. DeAngelo, J. G. Supko, F. D'Amato, D. Zahrieh, A. Sirulnik, M. Wadleigh, K. K. Ballen, S. McAfee, K. B. Miller, et al.
Phase I and Pharmacokinetic Study of Bortezomib in Combination with Idarubicin and Cytarabine in Patients with Acute Myelogenous Leukemia
Clin. Cancer Res.,
March 1, 2008;
14(5):
1446 - 1454.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Falini, C. Mecucci, G. Saglio, F. L. Coco, D. Diverio, P. Brown, F. Pane, M. Mancini, M. P. Martelli, S. Pileri, et al.
NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia
Haematologica,
March 1, 2008;
93(3):
439 - 442.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Marcondes, A. J. Mhyre, D. L. Stirewalt, S.-H. Kim, C. A. Dinarello, and H. J. Deeg
Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function
PNAS,
February 26, 2008;
105(8):
2865 - 2870.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Strehl, K. Nebral, M. Konig, J. Harbott, H. Strobl, R. Ratei, S. Struski, B. Bielorai, M. Lessard, M. Zimmermann, et al.
ETV6-NCOA2: A Novel Fusion Gene in Acute Leukemia Associated with Coexpression of T-Lymphoid and Myeloid Markers and Frequent NOTCH1 Mutations
Clin. Cancer Res.,
February 15, 2008;
14(4):
977 - 983.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Wandt, U. Schakel, F. Kroschinsky, G. Prange-Krex, B. Mohr, C. Thiede, U. Pascheberg, S. Soucek, M. Schaich, and G. Ehninger
MLD according to the WHO classification in AML has no correlation with age and no independent prognostic relevance as analyzed in 1766 patients
Blood,
February 15, 2008;
111(4):
1855 - 1861.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Teofili, R. Foa, F. Giona, and L. M. Larocca
Childhood polycythemia vera and essential thrombocythemia: does their pathogenesis overlap with that of adult patients?
Haematologica,
February 1, 2008;
93(2):
169 - 172.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Y. Kim, H.-J. Song, H.-J. Lim, M.-G. Shin, J. S. Kim, H.-J. Kim, B. Y. Kim, and S.-w. Lee
Platelet Factor-4 Is an Indicator of Blood Count Recovery in Acute Myeloid Leukemia Patients in Complete Remission
Mol. Cell. Proteomics,
February 1, 2008;
7(2):
431 - 441.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. van de Loosdrecht, T. M. Westers, A. H. Westra, A. M. Drager, V. H. J. van der Velden, and G. J. Ossenkoppele
Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry
Blood,
February 1, 2008;
111(3):
1067 - 1077.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Schmitt, A. Schmitt, M. T. Rojewski, J. Chen, K. Giannopoulos, F. Fei, Y. Yu, M. Gotz, M. Heyduk, G. Ritter, et al.
RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses
Blood,
February 1, 2008;
111(3):
1357 - 1365.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Pietra, S. Li, A. Brisci, F. Passamonti, E. Rumi, A. Theocharides, M. Ferrari, H. Gisslinger, R. Kralovics, L. Cremonesi, et al.
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders
Blood,
February 1, 2008;
111(3):
1686 - 1689.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Kurzrock, H. M. Kantarjian, M. A. Blascovich, C. Bucher, S. Verstovsek, J. J. Wright, S. R. Pilat, J. E. Cortes, E. H. Estey, F. J. Giles, et al.
Phase I Study of Alternate-Week Administration of Tipifarnib in Patients with Myelodysplastic Syndrome
Clin. Cancer Res.,
January 15, 2008;
14(2):
509 - 514.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Zebisch and H. Sill
Severe Hemolysis As Presenting Sign of Acute Erythroleukemia
J. Clin. Oncol.,
January 10, 2008;
26(2):
330 - 331.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Malcovati and M. Cazzola
Myelodysplastic/myeloproliferative disorders
Haematologica,
January 1, 2008;
93(1):
4 - 6.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. H. Schmitt-Graeff, S.-S. Teo, M. Olschewski, F. Schaub, S. Haxelmans, A. Kirn, P. Reinecke, U. Germing, and R. C. Skoda
JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis
Haematologica,
January 1, 2008;
93(1):
34 - 40.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Antonioli, P. Guglielmelli, G. Poli, C. Bogani, A. Pancrazzi, G. Longo, V. Ponziani, L. Tozzi, L. Pieri, V. Santini, et al.
Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia
Haematologica,
January 1, 2008;
93(1):
41 - 48.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Omidvar, S. Kogan, S. Beurlet, C. le Pogam, A. Janin, R. West, M.-E. Noguera, M. Reboul, A. Soulie, C. Leboeuf, et al.
BCL-2 and Mutant NRAS Interact Physically and Functionally in a Mouse Model of Progressive Myelodysplasia
Cancer Res.,
December 15, 2007;
67(24):
11657 - 11667.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Rumi, F. Passamonti, M. G. Della Porta, C. Elena, L. Arcaini, L. Vanelli, C. Del Curto, D. Pietra, E. Boveri, C. Pascutto, et al.
Familial Chronic Myeloproliferative Disorders: Clinical Phenotype and Evidence of Disease Anticipation
J. Clin. Oncol.,
December 10, 2007;
25(35):
5630 - 5635.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Barosi, G. Bergamaschi, M. Marchetti, A. M. Vannucchi, P. Guglielmelli, E. Antonioli, M. Massa, V. Rosti, R. Campanelli, L. Villani, et al.
JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis
Blood,
December 1, 2007;
110(12):
4030 - 4036.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. J.L. Kaspers and C. M. Zwaan
Pediatric acute myeloid leukemia: towards high-quality cure of all patients
Haematologica,
November 1, 2007;
92(11):
1519 - 1532.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Teofili, F. Giona, M. Martini, T. Cenci, F. Guidi, L. Torti, G. Palumbo, A. Amendola, G. Leone, R. Foa, et al.
The revised WHO diagnostic criteria for Ph-negative myeloproliferative diseases are not appropriate for the diagnostic screening of childhood polycythemia vera and essential thrombocythemia
Blood,
November 1, 2007;
110(9):
3384 - 3386.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Forghieri, M. Luppi, M. Morselli, L. Potenza, F. Volzone, G. Riva, A. Imovilli, E. Rivolti, and G. Torelli
Cytarabine-related lung infiltrates on high resolution computerized tomography: a possible complication with benign outcome in leukemic patients
Haematologica,
September 1, 2007;
92(9):
e85 - e90.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Pardanani, T. L. Lasho, C. Finke, R. A. Mesa, W. J. Hogan, R. P. Ketterling, D. G. Gilliland, and A. Tefferi
Extending Jak2V617F and MplW515 Mutation Analysis to Single Hematopoietic Colonies and B and T Lymphocytes
Stem Cells,
September 1, 2007;
25(9):
2358 - 2362.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Bullinger, F. G. Rucker, S. Kurz, J. Du, C. Scholl, S. Sander, A. Corbacioglu, C. Lottaz, J. Krauter, S. Frohling, et al.
Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia
Blood,
August 15, 2007;
110(4):
1291 - 1300.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Chang, B. E. Storer, B. L. Scott, E. M. Bryant, H. M. Shulman, M. E. Flowers, B. M. Sandmaier, R. P. Witherspoon, R. A. Nash, J. E. Sanders, et al.
Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders
Blood,
August 15, 2007;
110(4):
1379 - 1387.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi, J. Thiele, A. Orazi, H. M. Kvasnicka, T. Barbui, C. A. Hanson, G. Barosi, S. Verstovsek, G. Birgegard, R. Mesa, et al.
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel
Blood,
August 15, 2007;
110(4):
1092 - 1097.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Malcovati, U. Germing, A. Kuendgen, M. G. Della Porta, C. Pascutto, R. Invernizzi, A. Giagounidis, B. Hildebrandt, P. Bernasconi, S. Knipp, et al.
Time-Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic Syndromes
J. Clin. Oncol.,
August 10, 2007;
25(23):
3503 - 3510.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Vannucchi, E. Antonioli, P. Guglielmelli, A. Rambaldi, G. Barosi, R. Marchioli, R. M. Marfisi, G. Finazzi, V. Guerini, F. Fabris, et al.
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia
Blood,
August 1, 2007;
110(3):
840 - 846.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
